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Abstract
In patients with adrenal insufficiency, glucocorticoids (GCs) are insufficiently secreted and GC replacement is essential for health and, 
indeed, life. Despite GC-replacement therapy, patients with adrenal insufficiency have a greater cardiovascular risk than the general 
population, and suffer from impaired health-related quality of life. Although the aim of the replacement GC therapy is to reproduce as 
much as possible the physiological pattern of cortisol secretion by the normal adrenal gland, the pharmacokinetics of available oral 
immediate-release hydrocortisone or cortisone make it impossible to fully mimic the cortisol rhythm. Therefore, there is an unmet clinical 
need for the development of novel pharmaceutical preparations of hydrocortisone, in order to guarantee a more physiological serum 
cortisol concentration time-profile, and to improve the long-term outcome in patients under GC substitution therapy.
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In healthy subjects, cortisol, an endogenous glucocorticoid (GC), is 
secreted by the adrenal gland in a pulsatile and circadian fashion, with 
a peak release in the morning at wakening and a nadir at midnight.1 It 
has been demonstrated that loss of cortisol rhythmicity is associated 
with fatigue, depression and metabolic abnormalities, including insulin 
resistance.2,3 In patients with adrenal insufficiency, GCs are insufficiently 
secreted and substitutive GC replacement therapy is necessary.1,4–6
 
Hydrocortisone is the preferred replacement therapy for these patients 
worldwide, although in some countries this drug is not easily available and 
the preferred choice of GC substitution is cortisone acetate.4–6 Currently, 
GC doses prescribed for adults, based on cortisol production rate7 
and the practicality of taking oral drugs, are generally hydrocortisone 
15–20  mg/day or cortisone acetate 20–25  mg/day.6 Despite GC-
replacement therapy, patients with adrenal insufficiency present higher 
mortality rates compared with the general population, mainly from 
cardiovascular diseases,8,9 and they suffer from impaired health-related 
quality of life (QoL).10–14
Although the aim of the substitution therapy with GC is to replicate 
as much as possible the physiological pattern of cortisol secretion 
by the normal adrenal gland, the pharmacokinetics of available oral 
immediate-release GC, hydrocortisone or cortisone, make it impossible 
to fully mimic the cortisol rhythm.6 Therefore, there is an unmet clinical 
need for the development of novel pharmaceutical preparations of 
hydrocortisone to guarantee a more physiological serum cortisol 
concentration time-profile, and to improve the outcome in patients 
under GC substitution therapy.
Conventional Glucocorticoid Therapy –  
Limits (see Figure 1)
The major problem related to currently available GC preparations for 
replacement therapy is its lack of capacity to provide appropriate 
physiological replacement because of its pharmacokinetics.5,6,15 The 
cortisol levels following hydrocortisone and cortisone acetate intake 
show large inter-individual variation. Both drugs result in high serum 
cortisol levels right after tablet intake, and often immeasurable levels 
only few hours later.6
Hydrocortisone has a short plasma half-life and patients taking this 
tablet wake with undetectable cortisol levels, thus achieving peak 
cortisol levels an hour after dosing and very low levels of cortisol by 
mid-afternoon.16,17 The bioavailability of hydrocortisone after oral 
administration has been reported to be more than 90 % and the fraction 
of the dose adsorbed is accordingly more than 90  %.16,17 In addition, 
hydrocortisone has high intestinal permeability in vivo and in vitro.18 
Instead, dissolution rate kinetics in the gastrointestinal lumen are 
considered to be the rate-limiting step in the rate of intestinal absorption 
of hydrocortisone.16
The pharmacokinetics of immediate-release hydrocortisone make it 
impossible for physicians to replicate physiological cortisol release. 
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A number of research studies have explored different hydrocortisone 
regimes to try and identify the best doses and patterns of treatment. 
Patients on a thrice-daily regimen show levels of cortisol that are 
much more constant, which better mimic physiological cortisol rhythm 
compared with those on a twice-daily regimen.19 The use of weight-
adjusted dosing before food has been proposed as the regime able to 
decrease inter-patient variability in maximum cortisol concentration from 
31 to 7 %, and to reduce overexposure to <5 %; thus, thrice-daily weight-
adjusted dosing has been recommended as the preferred hydrocortisone 
regime.20 It is a clinical experience, however, in which patient compliance 
with thrice-daily dosing is far from absolute for many patients.
Another GC, preferred in some European countries, including Italy, is 
cortisone acetate, a prodrug that is converted to hydrocortisone by the 
enzyme 11b hydroxysteroid dehydrogenase (11bHSD1) type 1 and that 
possesses a GC activity equivalent to 0.8 that of hydrocortisone.5 Some 
authors oppose the use of cortisone acetate, since cortisone reductase 
(11bHSD1) deficiency has been described21 and renders cortisone inactive 
as replacement therapy.22 Moreover, the variable action of this enzyme 
could result in unpredictable cortisol effects after cortisone acetate. 
Compared with hydrocortisone, it presents a lower serum cortisol peak 
and possible delayed clearance of cortisol,23–25 which are properties 
that may be advantageous. At the same time, the difference in cortisol 
circulating levels after hydrocortisone or cortisone acetate replacement, 
and its clinical relevance, remain to be determined. As for hydrocortisone, 
a thrice-daily administration has been recommended as the preferred 
cortisone regime, as this regimen guarantees more physiological cortisol 
levels than twice-daily administration.26,27
Another major unsolved problem related to GC substitution therapy of 
adrenal insufficiency is monitoring the adequacy of the replacement, 
as no objective method or biomarker of cortisol activity has been 
demonstrated to be useful at this purpose.28 Some authors suggest that 
a simple, practical and effective way of monitoring cortisol is to measure 
a single serum cortisol 4 hours after dosing, and to compare this with a 
dosing nomogram that allows prediction of the cortisol and hence total 
cortisol exposure.20
At present, monitoring of GC replacement adequacy mostly relies on 
clinical assessment, which consists on the evaluation of clinical signs 
and symptoms suggestive for hypocortisolism (fatigue, abdominal or 
muscular pain, weight loss, hyperpigmentation) or hypercortisolism 
(weight gain, muscle weakness, psychiatric symptoms).6
Clinical scores of over- and under-replacement weakly correlate with 
cortisol concentrations. At the same time, cortisol concentrations 
themselves cannot distinguish between patients who feel over- or 
under-replaced and those who feel well-replaced.29 Finally, the long-term 
effects of GC substitution therapy remained to be determined. 
Once Addison’s disease is diagnosed and treated, life expectancy 
is considered normal and without complications,30 although during 
the last 6–7  years some studies have shown that replacement GC 
treatment might be involved in anthropometric and metabolic 
impairment with increased cardiovascular risk, namely if conventional 
doses are used.8,9
In particular, based on data collected from the National Swedish 
Hospital and Cause of Death Registers, Bergthorsdottir et al.8 reported 
an increased mortality in patients with adrenal insufficiency compared 
with the general population, mainly secondary to cardiovascular 
diseases and malignancies. Authors hypothesised that an excess of 
hydrocortisone dose, as well as the non-physiological daily pattern 
of cortisol peaks and nadirs, may be responsible for the increased 
mortality observed in these patients. 
Another Swedish study, linking the hospital discharge diagnosis 
to the National Death Register and Swedish Cancer Register also 
reported an overall standardised mortality rate of 2.7, with a peak of 
4.6 among patients with autoimmune polyendocrine syndrome type 
1 (APS1).9
The increased mortality in APS1 patients was also observed in a third 
Scandinavian study from Norway, in which the authors hypothesised 
that GC undertreatment might be potentially life-threatening.31
It has also been hypothesised that an altered circadian cortisol profile 
may be associated with an increased risk of abdominal obesity and the 
metabolic syndrome.32 Indeed, it is likely that the majority of patients 
in substitution therapy with hydrocortisone/cortisone acetate are 
overtreated; at the same time, the large interpersonal variability in 
daily need, intestinal absorption and carrier proteins concentrations, 
as well as GC-receptor polymorphism, make it difficult to translate the 
biochemical data to the clinical setting.6
Ongoing studies are testing the potential influence of polymorphisms 
of the GC receptor on the risk of metabolic complications in patients 
with Addison’s disease.33,34
Modified Hydrocortisone Preparation – 
Advantages
The first new preparation studied in clinical trials was a hydrocortisone 
preparation with a delayed and sustained release, consisting of an 
insoluble barrier coat covering all but one face of the tablet, with a 
slowly eroding layer retarding release from an inner drug containing 
layer (Chronocort®).35–37 The rationale of this preparation was to provide 
a peak in cortisol levels at wakening, and reproduce a more physiological 
daily cortisol serum profile. 
Figure 1: Serum Cortisol Levels after 
Administration of Three Daily Doses  
of Hydrocortisone or a Single Dual-release 
Hydrocortisone Preparation Compared with 
Physiological Average Concentration
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Serum cortisol levels after administration of three daily doses of hydrocortisone (dashed 
line) or a single dual-release hydrocortisone preparation (Plenadren® 20 mg) (dotted 
line) compared with physiological average concentration (continuous line). Permission 
obtained from Falorni et al., 2013.6
Dual-release Hydrocortisone in Addison’s Disease – A Review of the Literature 
EUROPEAN ENDOCRINOLOGY 77
This drug was tested in a pilot study of six healthy males whose 
endogenous cortisol had been suppressed by dexamethasone.35 Two 
formulations (15 mg unit dose) with predicted delayed release of 2 and 
4 hours were studied. The dose of 30 mg (two tablets) was administered 
at 22.00  hours. As expected, the measured serum cortisol showed 
delayed release, as expected, of 2 and 4 hours, with median peak cortisol 
concentrations at 4.5 and 10 hours, respectively. 
The results of the pilot study were later confirmed by an open-label, 
randomised, single-dose, crossover phase I study in 28 healthy subjects.36 
In this trial, the subjects were randomised to receive 5, 15 or 30 mg of 
Chronocort, administered at 22.00 hours. The profiles indicated a good 
match to the normal circadian profile overnight, but cortisol levels lower 
than normal after 12.00 hours on day 2, suggesting that it would not be 
suitable for just once-daily nocturnal dosing and that a second dose is to 
be assumed in the morning. A second dose of 10 mg is to be assumed in 
the morning for the daily need of late morning and afternoon.
A phase II study performed in patients with congenital adrenal hyperplasia 
(CAH) treated with a single dose of 30  mg Chronocort demonstrated 
a single cortisol peak at 6.00 hours and 17-hydroxyprogesterone 
concentrations significantly lower than those observed in patients 
treated with the conventional hydrocortisone preparation.37 However, 
high concentrations of 17-hydroxyprogesterone were observed in the 
afternoon, confirming the need for a second smaller dose in the morning. 
Overall, although the use of this delayed hydrocortisone preparation 
was shown to provide a more physiological cortisol serum profile 
compared with the conventional preparations of hydrocortisone, an 
important limit was a slightly higher cortisol night exposure, due to the 
fact that cortisol levels started to raise after 4 hours from the evening 
dose (around 2.00–3.00 hours) to reach the peak at wakening. 
No line of evidence supports the hypothesis that low cortisol exposure 
during the night may be a safety concern,38 while elevated cortisol levels 
in the late evening and at night (between midnight and 4.00 hours) may 
have detrimental effects on sleep quality and well-being39 and may 
provide the basis for long-term metabolic effects.
Another drug studied was a dual-release preparation of hydrocortisone 
(Duocort®, Plenadren®), which was formulated to have an immediate-
release coating and an internal core with delayed release, in order to 
obtain a rapid increase of cortisol levels in the morning and a prolonged 
lower release later. 
In a randomised, controlled, two-way crossover, double-blind, phase 
I study, Johannsson et al.40 investigated single-dose pharmacokinetics 
and dose-proportionality of oral 5 and 20  mg modified-release 
hydrocortisone tablets during fasting and fed conditions in 16 healthy 
volunteers. They demonstrated that the absorption of this drug was 
rapid (17–20 minutes for the 20 mg tablet in the fasted state) and that 
it was able to induce adequate increase of morning cortisol levels in 
all healthy subjects treated, with a time of peak concentration similar 
to that for conventional hydrocortisone (about 40–50  minutes). They 
also showed a more gradual decline in cortisol concentrations, as 
this drug provided an extended terminal half-life, about 1.0–1.5 hours 
longer than after administration of conventional tablet. This prolonged 
terminal half-life reduced or avoided the subnormal serum levels 
observed between 12.00 and 14.00 hours with the conventional 
hydrocortisone preparation. However, it was shorter enough to avoid 
supraphysiological afternoon cortisol levels observed with conventional 
hydrocortisone treatment and to provide a cortisol-free interval during 
night (see Figure 1). 
The 20 mg dose was also given 30 minutes after a high caloric breakfast 
and, compared with the fasting state, the intestinal absorption of 
hydrocortisone was delayed by about 60 minutes, but the cortisol profile 
was similar to that in fasting state. It is important from a safety aspect that 
concomitant food intake will not prevent absorption of hydrocortisone 
or impact on the predictability and appearance of the resulting plasma 
cortisol profile.
Thus, this new formulation has the potential for once-daily dosing, 
but cannot fully mimic the early morning cortisol peak, as the cortisol 
profile obtained with this new formulation is therefore slightly 
skewed in time. This was a choice taken in order to produce a safe 
product with high bioavailability of hydrocortisone with the lowest 
possible variability. 
More recently, the same authors published a phase II open, randomised, 
two-period, 12-week crossover multicentre trial with a 24-week 
extension at five university hospital centres, in 64 adult patients with 
adrenal insufficiency.41 The mean age was 47 years, the most common 
dose of hydrocortisone was 30 mg/day and less than 50  % had a 
twice-daily regime before the run-in period; 11 patients suffered from 
diabetes, and 11 were treated for hypertension.
The results of this study confirmed an improved serum cortisol 
profile with the dual-release formulation compared with conventional 
hydrocortisone treatment administered thrice-daily and with the same 
total daily dose (see Figure 1). The authors also demonstrated that the 
new preparation provided a higher serum cortisol profile during the first 
4 hours after morning intake and then gradually lower levels through the 
day, with a 24-hour cortisol exposure reduction of about 19.4 % in terms 
of conventional treatment. 
Interestingly, at the end of the 12-week treatment period with the dual-
release preparation, body weight significantly reduced in both the entire 
population of 64 patients and in 11 patients with concomitant diabetes. 
While no differences in fasting plasma glucose or insulin were observed 
between the treatments at 12 weeks, a significant reduction in glycated 
haemoglobin (HbA1c) was observed in both the entire population of 64 
patients (–0.1  % versus standard hydrocortisone) and in 11 patients 
with concomitant diabetes (–0.6 %). Less pronounced were the effects 
on lipid metabolism. In particular, total cholesterol and low-density 
lipoprotein (LDL)-cholesterol were not significantly different between 
the dual-release and the standard hydrocortisone preparations, while a 
small decrease in high-density lipoprotein (HDL) was reported in the total 
population, but not in the subgroup of patients with diabetes; a slightly 
increase in triglycerides was observed in the total population, either at 
12 week or at 24 week, while new formulation decreased triglycerides in 
patients with diabetes. A beneficial effect was also observed on systolic 
and diastolic blood pressure that decreased from baseline to 12 weeks 
of treatment with the dual-release (–5.5  mmHg and –2.3  mmHg, 
respectively), but not with standard hydrocortisone, namely in patients 
with normal to high blood pressure levels; no further changes in blood 
pressure occurred during the extension phase. 
In this study the authors also demonstrated some changes in bone 
markers, as mean concentrations of N-terminal propeptide of type I 
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procollagen and osteocalcin increased over 12 weeks of dual-release 
treatment, without any further change during the extension phase.
Notably, patients showed an improvement of the QoL as psychosocial 
functioning, cognitive functioning and positive well-being when 
taking the dual-release formulation compared with the conventional 
treatment. In the extension phase of the trial, 92 % of patients chose to 
continue the treatment with the dual-release formulation.
No significant differences in adverse events were recorded in the 
study between the two treatments (103 on new drug versus 75 on 
conventional treatment); the most commonly adverse events were 
nasopharyngitis, fatigue, gastroenteritis and influenza. Adverse events 
were more commonly reported during the first 8 weeks of the dual-
release formulation than during the second 3-month period. 
Thanks to the above mentioned results, the dual-release hydrocortisone 
preparation (Plenadren) was approved by the European Medicines 
Agency for the therapy of adrenal insufficiency. In particular, on 22 May 
2006, orphan designation (EU/3/06/372) was granted by the European 
Commission to DuoCort AB, Sweden, for hydrocortisone (modified-
release tablet) for the treatment of adrenal insufficiency. The sponsorship 
was transferred to DuoCort Pharma AB, Sweden, in November 2008 and 
subsequently to ViroPharma SPRL, Belgium, in February 2012.
Preliminary data have already been published as Abstracts at 
International Congresses. In particular, Simeoli et al. reported an 
improvement in weight, waist circumference and QoL in a group of 
12 patients with adrenal insufficiency after 3 months of Plenadren 
treatment at doses ranging from 15 to 40  mg/day.42 The European 
Adrenal Insufficiency Registry (EUAIR), which was started in August 
2012 as a multinational, observational study of patients with primary 
or secondary adrenal insufficiency, will provide opportunities to collect 
long-term safety data related to the use of Plenadren.43
Conclusion
After over 50 years of conventional hydrocortisone/cortisone acetate 
treatment, a novel drug is entering the routine practice of clinical 
management of adrenal insufficiency. The dual-release hydrocortisone 
preparation combines several interesting characteristics, as it 
guarantees a rapid release of hydrocortisone early in the morning, 
when needed most, with a prolonged lower effect during the day, 
thus making a single administration a day possible, which is certainly 
important to improve patient compliance. The more physiological 
serum cortisol profile observed with the dual-release preparation 
compared with the conventional hydrocortisone treatment, although 
not able to fully replicate all aspects of an intact hypothalamus–
pituitary–adrenal axis, offers the prospect of improved biochemical 
control and QoL. ■
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